MIRA Pharmaceuticals Inc. has announced the publication of a manuscript detailing its lead drug candidate, Ketamir-2, in the peer-reviewed journal Frontiers in Pharmacology. The manuscript, authored by Dr. Itzchak Angel, highlights Ketamir-2 as a novel ketamine analog with a differentiated pharmacological profile. Currently undergoing a Phase 1 clinical trial for neuropathic pain, Ketamir-2 has shown no safety concerns, with dose escalation advancing as planned. MIRA aims to initiate a Phase 2a clinical trial by the end of 2025, subject to regulatory approval. The publication underscores Ketamir-2's potential as a safer alternative to ketamine, with a focus on addressing limitations such as poor oral bioavailability and dissociative side effects. Further scientific data submissions and presentations are in preparation to support its clinical development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.